title: [Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer].
abstract: OBJECTIVE
  We assessed the antitumor response and safety of neoadjuvant chemotherapy (NAC) using cisplatin (CDDP) and irinotecan(CPT-11)given every three weeks for locally advanced cervical cancer with a bulky mass.
  
  
  METHODS
  Nineteen patients with cervical squamous cell cancer in FIGO stage of Ib2 to IIb were enrolled in this study. The FIGO stages were Ib2 in 5 patients, IIa in 2 patients, and IIb in 12 patients. One course of the chemotherapy regimen consisted of intravenous administrations of CDDP at a dose of 70 mg/m 2(day 1)and CPT-11 at 70 mg/m 2 (days 1 and 8) for 21 days, and two courses were administered. This chemotherapy was assessed for antitumor response, adverse events, complete surgical removal rate, progression-free survival time, and overall survival time. RECIST and NCI-CTCAE were used to determine antitumor response and adverse events, respectively.
  
  
  RESULTS
  The results of assessment of the antitumor response showed CR in 3 patients(15. 8%), PR in 14(73. 7%), SD in 1 (5. 3%), and PD in 1(5. 3%). Neutropenia of grade 3 or higher occurred in 13 patients(68. 4%). Anemia occurred in 2 patients(10. 5%), and thrombocytopenia in 1 patient(5. 3%). Nausea and vomiting were observed in 2 patients(10. 5%). All patients underwent a chemotherapy regimen consisting of two courses, and the rate of complete surgical removal was 94. 7%. The median observation period was 27 months; the progression-free survival time was 18 months, and survival time was 27 months.
  
  
  CONCLUSIONS
  Adverse drug reactions to NAC with the CDDP/CPT-11 combination administered every three weeks were controllable. The antitumor response rate for this chemotherapy was high. These assessment results indicate that NAC with a CDDP/CPT-11 combination was useful for local advanced cervical cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine.
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Shoji
authors.forename: Eriko
authors.initials: E
authors.lastname: Takatori
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Murai
authors.forename: Shinya
authors.initials: S
authors.lastname: Hatayama
authors.forename: Hideo
authors.initials: H
authors.lastname: Omi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kagabu
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Honda
authors.forename: Seisuke
authors.initials: S
authors.lastname: Kumagai
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Morohara
authors.forename: Akira
authors.initials: A
authors.lastname: Yoshizaki
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Kaido
authors.forename: Fumiharu
authors.initials: F
authors.lastname: Miura
authors.forename: Akira
authors.initials: A
authors.lastname: Satoh
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin